Evaxion Biotech A/S (NASDAQ:EVAX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAXFree Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $14.00 target price on the stock.

Separately, LADENBURG THALM/SH SH upgraded Evaxion Biotech A/S from a neutral rating to a buy rating and set a $8.00 price target on the stock in a research report on Tuesday, April 2nd.

View Our Latest Analysis on Evaxion Biotech A/S

Evaxion Biotech A/S Price Performance

NASDAQ:EVAX opened at $3.52 on Tuesday. Evaxion Biotech A/S has a 1 year low of $2.82 and a 1 year high of $18.50. The company has a market cap of $19.05 million, a P/E ratio of -0.81 and a beta of -0.24. The stock’s fifty day moving average price is $3.84 and its two-hundred day moving average price is $5.03.

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) last issued its quarterly earnings data on Wednesday, March 27th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.07 million during the quarter. On average, analysts expect that Evaxion Biotech A/S will post -0.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Beacon Capital Management LLC grew its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAXFree Report) by 606.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,633 shares of the company’s stock after buying an additional 41,752 shares during the quarter. Beacon Capital Management LLC owned 0.17% of Evaxion Biotech A/S worth $33,000 at the end of the most recent quarter. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.

Featured Articles

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.